Drug Profile
CH 715
Latest Information Update: 13 Jan 1997
Price :
$50
*
At a glance
- Originator Celltech Group
- Class Antineoplastics; Antirheumatics
- Mechanism of Action Metalloprotease inhibitors; Peptide hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Inflammation; Rheumatoid arthritis
Most Recent Events
- 13 Jan 1997 Discontinued-Preclinical for Cancer in United Kingdom (Unknown route)
- 13 Jan 1997 Discontinued-Preclinical for Inflammation in United Kingdom (Unknown route)
- 13 Jan 1997 Discontinued-Preclinical for Rheumatoid arthritis in United Kingdom (Unknown route)